{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(5)"],"submitter":["Huang RSP"],"pubmed_abstract":["<h4>Introduction</h4>Several studies have shown clinical outcomes data that support the use of <i>CD274 (PD-L1</i>) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of <i>CD274</i> CN changes across a large cohort of solid tumor cases and correlate these with PD-L1 protein expression by immunohistochemistry.<h4>Methods</h4>We analyzed all cases that underwent comprehensive genomic profiling (CGP) testing at Foundation Medicine between August 2014 and June 2020. <i>CD274</i> CN changes were correlated with PD-L1 expression in tumor types where there were Food and Drug Administration approved companion diagnostic (CDx) claims and the CDx assay was used to assess PD-L1 expression.<h4>Results</h4>In all, 244 584 samples "],"journal":["Journal for immunotherapy of cancer"],"pagination":["e002680"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8112409"],"repository":["biostudies-literature"],"pubmed_title":["Pan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression."],"pmcid":["PMC8112409"],"pubmed_authors":["Decker B","Albacker LA","Murugesan K","Hiemenz MC","Huang RSP","Mata DA","Pavlick DC","Ross JS","Montesion M","Frampton G"],"additional_accession":[]},"is_claimable":false,"name":"Pan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.","description":"<h4>Introduction</h4>Several studies have shown clinical outcomes data that support the use of <i>CD274 (PD-L1</i>) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of <i>CD274</i> CN changes across a large cohort of solid tumor cases and correlate these with PD-L1 protein expression by immunohistochemistry.<h4>Methods</h4>We analyzed all cases that underwent comprehensive genomic profiling (CGP) testing at Foundation Medicine between August 2014 and June 2020. <i>CD274</i> CN changes were correlated with PD-L1 expression in tumor types where there were Food and Drug Administration approved companion diagnostic (CDx) claims and the CDx assay was used to assess PD-L1 expression.<h4>Results</h4>In all, 244 584 samples ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-07-16T09:57:41.471Z","creation":"2026-07-09T10:49:40.001Z"},"accession":"S-EPMC8112409","cross_references":{"pubmed":["33972391"],"doi":["10.1136/jitc-2021-002680"]}}